Edelson Lechtzin LLP Launches Investigation into Outset Medical amid Investor Losses

Investigation of Outset Medical, Inc.

Edelson Lechtzin LLP, a prominent national class action law firm, has initiated an investigation concerning the operations of Outset Medical, Inc. (NASDAQ: OM) in light of recent substantial financial losses reported by the company. The investigation focuses on potential violations of federal securities laws, primarily regarding misleading business information disseminated to investors.

The Context of the Investigation

On November 10, 2025, Outset Medical released its financial results for the third quarter of 2025. The company reported a disappointing earnings per share (EPS) of -$0.69, which was $0.03 short of analysts’ consensus estimates. Furthermore, Outset Medical’s revenue came in at $29.43 million, falling short of expectations by $1.27 million. This disheartening news not only contributed to the firm lowering its full-year 2025 revenue guidance from $122–$126 million to $115–$120 million, but it also indicated delays in achieving several anticipated business opportunities.

Following this announcement, the market reacted negatively, resulting in a staggering drop in Outset Medical's stock price. On November 11, 2025, the shares plummeted by $5.85, or 48.47%, closing at $6.22 per share. This significant decline led many investors to question the integrity of the information provided by the company, prompting Edelson Lechtzin to encourage those who might have suffered losses to come forward for assistance.

Outset Medical: An Overview

Based in San Jose, California, Outset Medical is a medical technology company dedicated to innovating the field of hemodialysis. The company is best known for its Tablo Hemodialysis System, which aims to provide a user-friendly dialysis experience for patients needing this critical treatment. Despite its innovative products, the recent financial missteps have raised eyebrows and led many stakeholders to seek clarity regarding the company's future performance and governance.

The Role of Edelson Lechtzin LLP

Edelson Lechtzin LLP has a track record of handling complex class action cases, particularly regarding securities and investment fraud. The firm specializes in representing investors who may have faced financial losses due to corporate malfeasance. Investors with non-public information relevant to the investigation are encouraged to reach out to the firm, which is prepared to help navigate the legal landscape surrounding these allegations. Interested parties can contact attorney Eric Lechtzin directly at 844-563-5550 or via email to obtain more details about their potential claims.

Conclusion

As this investigation progresses, the implications for Outset Medical and its shareholders could be significant. Investors who believe they might be affected or have information that could assist in the inquiry should not hesitate to reach out to Edelson Lechtzin LLP for guidance and support. The firm remains committed to holding companies accountable for any breaches of investor trust and conveying transparent information. Keep an eye on this developing story as it unfolds and impacts not just Outset Medical, but potentially the broader medical technology market as well.